ML-02 MULTIAGENT IMMUNOCHEMOTHERAPY, R-MPV-A, FOR PATIENTS WITH SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA

BACKGROUNDS: Standard of care (SOC) for primary central nervous system lymphoma (PCNSL) has been induction therapy with high-dose methotrexate (MTX)-based multiagent immunochemotherapies followed by consolidation, and we have shown that one such regimen, R-MPV-A have superior efficacy over HD-MTX al...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagane, Motoo, Kobayashi, Keiichi, Saito, Kuniaki, Shimada, Daisuke, Matsumoto, Yoshie, Iijima, Shohei, Sasaki, Nobuyoshi, Yamagishi, Yuki, Takayama, Nobuyuki, Shiokawa, Yoshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213230/
http://dx.doi.org/10.1093/noajnl/vdz039.145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213230/
http://dx.doi.org/10.1093/noajnl/vdz039.145

Ejemplares similares